Literature DB >> 23183307

Current controversies in breast cancer surgery.

A C Critchley1, A M Thompson, H Y Chan, M W Reed.   

Abstract

Contemporary management of the axilla in breast cancer surgery remains in evolution. Axillary lymph node status in breast cancer is a major prognostic factor and remains integral to guiding adjuvant treatment decisions. There remains controversy regarding the management of the node-positive axilla in clinically node-negative primary breast cancer. Trials to date have suggested re-evaluation of the historical therapeutic strategy that a positive sentinel node requires axillary node dissection. However, further evidence is required before modern clinical management of the axilla should be altered. As patient awareness and technical expertise grow, national rates of breast reconstruction after mastectomy continue to rise. Oncoplastic techniques continue to evolve and many patients are suitable for a plethora of reconstructive options. Despite the widespread practice of breast reconstruction globally, there is limited randomised evidence comparing the optimal type and/or timing of breast reconstruction on which to base practice. Breast reconstruction type is either purely autologous, implant-based or a combination of these two techniques. We explore the benefits and limitations of these techniques and some of the key findings of the National Mastectomy and Breast Reconstruction Audit. The timing of reconstruction after mastectomy is either immediate (a single procedure) or delayed (for an indefinite period after mastectomy). The ideal reconstruction is one that is best aligned to the patient's expectations, as this will achieve the highest levels of long-term patient satisfaction. Selecting the optimal type of breast reconstruction at the right time for the right patient remains the key challenge in breast reconstruction.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23183307     DOI: 10.1016/j.clon.2012.10.009

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  Bioprinting predifferentiated adipose-derived mesenchymal stem cell spheroids with methacrylated gelatin ink for adipose tissue engineering.

Authors:  Julien Colle; Phillip Blondeel; Axelle De Bruyne; Silke Bochar; Liesbeth Tytgat; Chris Vercruysse; Sandra Van Vlierberghe; Peter Dubruel; Heidi Declercq
Journal:  J Mater Sci Mater Med       Date:  2020-03-23       Impact factor: 3.896

2.  BREAST trial study protocol: evaluation of a non-invasive technique for breast reconstruction in a multicentre, randomised controlled trial.

Authors:  Sander S J Schop; Juliette E Hommes; Todor K Krastev; Daniëlle Derks; Mikko Larsen; HInne Rakhorst; Ute Schmidbauer; Jan Maerten Smit; Tik Tan; Kim Wehrens; Thijs de Wit; Rene R W J van der Hulst; Andrzej A Piatkowski de Grzymala
Journal:  BMJ Open       Date:  2021-09-16       Impact factor: 2.692

3.  Human fibroblasts facilitate the generation of iPSCs-derived mammary-like organoids.

Authors:  Xueqin Dai; Xinye Wang; Chuanyu Yang; Maobo Huang; Zhongmei Zhou; Ying Qu; Xiaojiang Cui; Rong Liu; Ceshi Chen
Journal:  Stem Cell Res Ther       Date:  2022-07-28       Impact factor: 8.079

Review 4.  Adipose-Derived Stem Cells in Novel Approaches to Breast Reconstruction: Their Suitability for Tissue Engineering and Oncological Safety.

Authors:  Niamh O'Halloran; Donald Courtney; Michael J Kerin; Aoife J Lowery
Journal:  Breast Cancer (Auckl)       Date:  2017-08-16

Review 5.  Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Authors:  Suzanne A Eccles; Eric O Aboagye; Simak Ali; Annie S Anderson; Jo Armes; Fedor Berditchevski; Jeremy P Blaydes; Keith Brennan; Nicola J Brown; Helen E Bryant; Nigel J Bundred; Joy M Burchell; Anna M Campbell; Jason S Carroll; Robert B Clarke; Charlotte E Coles; Gary J R Cook; Angela Cox; Nicola J Curtin; Lodewijk V Dekker; Isabel dos Santos Silva; Stephen W Duffy; Douglas F Easton; Diana M Eccles; Dylan R Edwards; Joanne Edwards; D Evans; Deborah F Fenlon; James M Flanagan; Claire Foster; William M Gallagher; Montserrat Garcia-Closas; Julia M W Gee; Andy J Gescher; Vicky Goh; Ashley M Groves; Amanda J Harvey; Michelle Harvie; Bryan T Hennessy; Stephen Hiscox; Ingunn Holen; Sacha J Howell; Anthony Howell; Gill Hubbard; Nick Hulbert-Williams; Myra S Hunter; Bharat Jasani; Louise J Jones; Timothy J Key; Cliona C Kirwan; Anthony Kong; Ian H Kunkler; Simon P Langdon; Martin O Leach; David J Mann; John F Marshall; Lesley Martin; Stewart G Martin; Jennifer E Macdougall; David W Miles; William R Miller; Joanna R Morris; Sue M Moss; Paul Mullan; Rachel Natrajan; James P B O'Connor; Rosemary O'Connor; Carlo Palmieri; Paul D P Pharoah; Emad A Rakha; Elizabeth Reed; Simon P Robinson; Erik Sahai; John M Saxton; Peter Schmid; Matthew J Smalley; Valerie Speirs; Robert Stein; John Stingl; Charles H Streuli; Andrew N J Tutt; Galina Velikova; Rosemary A Walker; Christine J Watson; Kaye J Williams; Leonie S Young; Alastair M Thompson
Journal:  Breast Cancer Res       Date:  2013-10-01       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.